AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26836415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 26
Study 26836415 — intervention group
Group type: COMPARATOR
Intervention: Attention bias modification control treatment
Number of subjects: 26
Study 26836415 — intervention group
Group type: COMPARATOR
Intervention: Socially anxious participants (compared to healthy controls)
Number of subjects: 26
Study 25335376 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐Fluorouracil (5‐FU) plus CAG
Number of subjects: 80
Study 25335376 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (MMC) plus CAG
Number of subjects: 80
Study 25335376 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 80
Study 25335376 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 80
Study 25335376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygium size
Number of subjects: 80
Study 25335376 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 80
Study 25335376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygium morphology
Number of subjects: 80
Study 23511558 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial participation (RCT acceptance)
Number of subjects: 486
Study 23511558 — intervention group
Group type: COMPARATOR
Intervention: Trial decliners
Number of subjects: 486
Study 23511558 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for trial acceptance
Number of subjects: 486
Study 23511558 — intervention group
Group type: COMPARATOR
Intervention: Reasons for trial declining
Number of subjects: 486
Study 23511558 — intervention group
Group type: COMPARATOR
Intervention: Preference for treatment decision
Number of subjects: 486
Study 23511558 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of doctors' attitudes towards trial participation
Number of subjects: 486
Study 20307227 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0
Study 20307227 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 25159906 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use promotion leaflet with quiz and prize draw
Number of subjects: 404
Study 25159906 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no leaflet or incentive)
Number of subjects: 404
Study 16507967 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive counselling
Number of subjects: 0
Study 16507967 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 0
Study 16507967 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 12567169 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 209
Study 12567169 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 209
Study 11334233 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 8851527 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intensity at 73W (Ex-1)
Number of subjects: 6
Study 8851527 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intensity at 103W (Ex-2)
Number of subjects: 6
Study 8851527 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intensity at 133W (Ex-3)
Number of subjects: 6
Study 8851527 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 6
Study 1729617 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 micrograms twice a day)
Number of subjects: 622
Study 1729617 — intervention group
Group type: COMPARATOR
Intervention: Calcium (1 g of elemental calcium daily)
Number of subjects: 622
Study 6390463 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg tiaprofenic acid per day, in 3 divided doses
Number of subjects: 80
Study 6390463 — intervention group
Group type: COMPARATOR
Intervention: 75 mg indomethacin per day, in 3 divided doses
Number of subjects: 80
Study 30854006 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal toothpaste containing Rhizoma Chuanxiong and Rhizoma Imperatae extracts
Number of subjects: 120
Study 30854006 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 120
Study 28236511 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 308
Study 28236511 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 308
Study 26188490 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive nutritional support
Number of subjects: 53
Study 26188490 — intervention group
Group type: COMPARATOR
Intervention: On demand nutritional support
Number of subjects: 53
Study 24477179 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study 24477179 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 22066827 — intervention group
Group type: EXPERIMENTAL
Intervention: PPE (9 capsules/day) as adjunctive therapy combined with HRT
Number of subjects: 48
Study 22066827 — intervention group
Group type: COMPARATOR
Intervention: Calcium (260 mg/day) as adjunctive therapy combined with HRT
Number of subjects: 48
Study 19588499 — intervention group
Group type: EXPERIMENTAL
Intervention: PicoGreen assay
Number of subjects: 176
Study 19588499 — intervention group
Group type: EXPERIMENTAL
Intervention: QRTPCR
Number of subjects: 176
Study 19588499 — intervention group
Group type: EXPERIMENTAL
Intervention: PicoGreen assay at cut-off point of 2.5 microg/ml
Number of subjects: 176
Study 19588499 — intervention group
Group type: EXPERIMENTAL
Intervention: PicoGreen assay at cut-off point of 5.0 microg/ml
Number of subjects: 176
Study 18041414 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream
Number of subjects: 120
Study 18041414 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 120
Study 16218910 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary clipping used in 22 patients (group A)
Number of subjects: 40
Study 16218910 — intervention group
Group type: COMPARATOR
Intervention: No temporary clipping used in 18 patients (group B)
Number of subjects: 40
Study 16218910 — intervention group
Group type: COMPARATOR
Intervention: Control group of 20 volunteers (group C) without neurologic or psychiatric disorders
Number of subjects: 40
Study 12360164 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of atorvastatin every other day
Number of subjects: 35
Study 12360164 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of atorvastatin every day
Number of subjects: 35
Study 12360164 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean dose of atorvastatin in alternate-day group
Number of subjects: 35
Study 12360164 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean dose of atorvastatin in every-day group
Number of subjects: 35
Study 10428529 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol valerate 2 mg daily for six months
Number of subjects: 67
Study 10428529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 7482063 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 190
Study 7482063 — intervention group
Group type: COMPARATOR
Intervention: Salazosulfapyridine
Number of subjects: 190
Study 2184514 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 112
Study 2184514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 7233907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear-acupuncture
Number of subjects: 13
Study 7233907 — intervention group
Group type: COMPARATOR
Intervention: Placebo-acupuncture
Number of subjects: 13
Study 30934166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 16
Study 30934166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 16
Study 30934166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin (5 mg and 15 mg)
Number of subjects: 16
Study 29779795 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga Nidra recording
Number of subjects: 144
Study 29779795 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation music
Number of subjects: 144
Study 29779795 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 144
Study 29548302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated approach (community health worker solely responsible for delivering mental health care)
Number of subjects: 1200
Study 29548302 — intervention group
Group type: EXPERIMENTAL
Intervention: Designated approach (community health worker provides mental health care in addition to usual responsibilities)
Number of subjects: 1200
Study 29548302 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 1200
Study 27295489 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg immediate-release tapentadol
Number of subjects: 0
Study 27295489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24880956 — intervention group
Group type: EXPERIMENTAL
Intervention: EAS prompting with 4% CHG (Group A1)
Number of subjects: 80
Study 24880956 — intervention group
Group type: EXPERIMENTAL
Intervention: EAS prompting with 4% CHG (Group B1)
Number of subjects: 80
Study 24880956 — intervention group
Group type: COMPARATOR
Intervention: Non-EAS (Group A2)
Number of subjects: 80
Study 24880956 — intervention group
Group type: COMPARATOR
Intervention: Non-EAS (Group B2)
Number of subjects: 80
Study 22098077 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients (group 1)
Number of subjects: 110
Study 22098077 — intervention group
Group type: COMPARATOR
Intervention: Patients with chronic kidney disease (group 2)
Number of subjects: 110
Study 22098077 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (group 3)
Number of subjects: 110
Study 19394731 — intervention group
Group type: EXPERIMENTAL
Intervention: 46.7% sodium citrate
Number of subjects: 232
Study 19394731 — intervention group
Group type: COMPARATOR
Intervention: 5% heparin
Number of subjects: 232
Study 17615904 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate (10 mg elemental zinc) added to multi-vitamin syrup containing vitamin A
Number of subjects: 200
Study 17615904 — intervention group
Group type: COMPARATOR
Intervention: Multi-vitamin syrup containing vitamin A (control group)
Number of subjects: 200
Study 18771134 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 77
Study 11992160 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent rhesus‐human rotavirus vaccine (3 doses at 1st, 3rd, and 5th months of life)
Number of subjects: 93
Study 11992160 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent rhesus‐human rotavirus vaccine
Number of subjects: 93
Study 10379269 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium restorations
Number of subjects: 110
Study 10379269 — intervention group
Group type: COMPARATOR
Intervention: Gold alloy restorations
Number of subjects: 110
Study 8732146 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 40
Study 8732146 — intervention group
Group type: COMPARATOR
Intervention: Filiform needle acupuncture (FNA)
Number of subjects: 40
Study 2496428 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg intravenous (IV) cocaine with 2.5 mg oral bromocriptine pretreatment
Number of subjects: 9
Study 2496428 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg intravenous (IV) cocaine without bromocriptine pretreatment
Number of subjects: 9
Study 2496428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1090892 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and vincristine therapy
Number of subjects: 37
Study 1090892 — intervention group
Group type: COMPARATOR
Intervention: Vincristine alone
Number of subjects: 37
Study 1090892 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic prednisone therapy
Number of subjects: 37
Study 1090892 — intervention group
Group type: COMPARATOR
Intervention: Control group of nephrotic syndrome patients not treated with prednisone
Number of subjects: 37
Study 1090892 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone dosage
Number of subjects: 37
Study 30936683 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 90
Study 30936683 — intervention group
Group type: COMPARATOR
Intervention: Volume-matched normal saline (Group C)
Number of subjects: 90
Study 28233020 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 40
Study 28233020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26296539 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily for 14 weeks
Number of subjects: 393
Study 26296539 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 14 weeks
Number of subjects: 393
Study 26296539 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 393
Study 22778174 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinaciguat (100 μg/h starting dose, continuous i.v. infusion, titrated for 8 h and maintained for 16-40 h)
Number of subjects: 139
Study 22778174 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinaciguat
Number of subjects: 139
Study 22778174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 21740986 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 7
Study 21740986 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 7
Study 18633013 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 50
Study 18633013 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid
Number of subjects: 50
Study 17068190 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-month Wa Do Ryu karate program
Number of subjects: 16
Study 17068190 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 16
Study 14506950 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K1 (1 mg/day) with mineral + vitamin D supplement (8 microg/day)
Number of subjects: 181
Study 14506950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 14506950 — intervention group
Group type: COMPARATOR
Intervention: Mineral + vitamin D supplement (MD group)
Number of subjects: 181
Study 11320158 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil augmentation
Number of subjects: 1
Study 11320158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 9988017 — intervention group
Group type: EXPERIMENTAL
Intervention: Derived ECGs
Number of subjects: 129
Study 9988017 — intervention group
Group type: COMPARATOR
Intervention: Standard ECGs
Number of subjects: 129
Study 7761959 — intervention group
Group type: EXPERIMENTAL
Intervention: Loderix (setastine)
Number of subjects: 10
Study 7761959 — intervention group
Group type: COMPARATOR
Intervention: Teldane (terfenadine)
Number of subjects: 10
Study 7761959 — intervention group
Group type: COMPARATOR
Intervention: Suprastin (chloropyramine HCl)
Number of subjects: 10
Study 2904053 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg twice a day)
Number of subjects: 8
Study 2904053 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine (8 g twice a day)
Number of subjects: 8
Study 4847317 — intervention group
Group type: EXPERIMENTAL
Intervention: Jogging program (25 weeks, primarily jogging with some calisthenics)
Number of subjects: 22
Study 4847317 — intervention group
Group type: COMPARATOR
Intervention: Games program (equal time spent in swimming, volleyball, and bowling)
Number of subjects: 22
Study 4847317 — intervention group
Group type: EXPERIMENTAL
Intervention: Jogging program
Number of subjects: 22
Study 4847317 — intervention group
Group type: COMPARATOR
Intervention: Games program
Number of subjects: 22
Study 31551368 — intervention group
Group type: EXPERIMENTAL
Intervention: IONIS‐APO(a)Rx (antisense oligonucleotide directed to apo(a))
Number of subjects: 17
Study 31551368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31551368 — intervention group
Group type: EXPERIMENTAL
Intervention: IONIS‐APO(a)Rx
Number of subjects: 17
Study 28606235 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy combined with Lactobacillus
Number of subjects: 416
Study 28606235 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy combined with Lactobacillus
Number of subjects: 416
Study 28606235 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy
Number of subjects: 416
Study 28606235 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 416
Study 28606235 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential-Lactobacillus group
Number of subjects: 416
Study 28606235 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-Lactobacillus group
Number of subjects: 416
Study 28606235 — intervention group
Group type: COMPARATOR
Intervention: Sequential group
Number of subjects: 416
Study 28606235 — intervention group
Group type: COMPARATOR
Intervention: Triple group
Number of subjects: 416
Study 25606700 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg subcutaneously every 2 weeks
Number of subjects: 103
Study 25606700 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg per os every day
Number of subjects: 103
Study 23036567 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV group (previous 23-gauge PPV and ILM peeling)
Number of subjects: 35
Study 23036567 — intervention group
Group type: COMPARATOR
Intervention: Control group (senile cataract with healthy macula)
Number of subjects: 35
Study 21317223 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV+ patients
Number of subjects: 264
Study 21317223 — intervention group
Group type: COMPARATOR
Intervention: HPV- patients
Number of subjects: 264
Study 19736427 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch and photopatch testing for allergic and photoallergic reactions to parthenium, xanthium, and chrysanthemum plant antigens
Number of subjects: 156
Study 19736427 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 156
Study 16364168 — intervention group
Group type: COMPARATOR
Intervention: Wheat allergen repertoire screening
Number of subjects: 21
Study 16364168 — intervention group
Group type: COMPARATOR
Intervention: Maize allergen repertoire screening
Number of subjects: 21
Study 16364168 — intervention group
Group type: COMPARATOR
Intervention: Evaluation of IgE-binding capacity of selected proteins
Number of subjects: 21
Study 15042136 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape-seed extract
Number of subjects: 51
Study 15042136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 11761026 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular dose of omeprazole (20 mg once a day for 3 days, i.e. 60 mg/72 h)
Number of subjects: 142
Study 11761026 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of omeprazole (80 mg bolus + 8 mg/h for 3 days, i.e. 652 mg/72 h)
Number of subjects: 142
Study 9259655 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 150 mg orally twice a day
Number of subjects: 202
Study 9259655 — intervention group
Group type: COMPARATOR
Intervention: placebo orally twice a day
Number of subjects: 202
Study 30341268 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash with super-oxidized solution (SOS) Dermacyn® Wound Care
Number of subjects: 20
Study 30341268 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gel (CHX)
Number of subjects: 20
Study 27558002 — intervention group
Group type: EXPERIMENTAL
Intervention: NOAC group (dabigatran or rivaroxaban)
Number of subjects: 0
Study 27558002 — intervention group
Group type: COMPARATOR
Intervention: Warfarin group
Number of subjects: 0
Study 24501143 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 211
Study 24501143 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed messages
Number of subjects: 211
Study 22942727 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA + ER‐DP
Number of subjects: 425
Study 22942727 — intervention group
Group type: COMPARATOR
Intervention: ASA monotherapy
Number of subjects: 425
Study 18929360 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of oral micronized progesterone (OMP) twice a day
Number of subjects: 150
Study 18929360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 16883627 — intervention group
Group type: EXPERIMENTAL
Intervention: Chunghyul-dan (CHD) 600 mg three times a day for 8 weeks
Number of subjects: 35
Study 16883627 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication, observation only)
Number of subjects: 35
Study 15325864 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 50 microg four hourly to maximum of 5 doses
Number of subjects: 70
Study 15325864 — intervention group
Group type: COMPARATOR
Intervention: Continuous oxytocin infusion
Number of subjects: 70
Study 11391688 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental net benefit expressed in units of cost
Number of subjects: 0
Study 11391688 — intervention group
Group type: COMPARATOR
Intervention: Cost minimization approach
Number of subjects: 0
Study 11391688 — intervention group
Group type: COMPARATOR
Intervention: Incremental cost-effectiveness approach
Number of subjects: 0
Study 11391688 — intervention group
Group type: COMPARATOR
Intervention: Incremental net benefit approach
Number of subjects: 0
Study 9591893 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 97
Study 9591893 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 97
Study 7843390 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoharringtonine (H.H)
Number of subjects: 47
Study 7843390 — intervention group
Group type: COMPARATOR
Intervention: 5-Fluorouracil (5-FU)
Number of subjects: 47
Study 2978461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulization treatment with terbutaline and ipratropium bromide (given separately with a 30‐minute interval or combined as single inhalation)
Number of subjects: 77
Study 2978461 — intervention group
Group type: COMPARATOR
Intervention: Injection treatment with terbutaline (subcutaneously) and theophylline (intravenously)
Number of subjects: 77